Subtype
Malignant Endometrial Neoplasm
CI-CAN-00008980Explore in graph →
359 active trials4 approved drugs28 evidence items
Loading cancer entity…
Subtype
CI-CAN-00008980Explore in graph →
Clinical trials
1,198 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (112)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05876130 | Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer | recruiting | N/A | 92 | Samsung Medical CenterOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06293066 | Performance of Ultrasound in Women With Postmenopausal or Abnormal Uterine Bleeding Between White and Black Ethnic Groups- a Retrospective Cohort Study. | unknown | — | 330 | King's College Hospital NHS TrustOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT06250010 | Immunotolerance in Endometrial Cancer and at the Maternal-fetal Interface: Immunological Profiling of the Tumor Microenvironment in Risk Stratification of Recurrence | unknown | — | 30 | Regina Elena Cancer InstituteOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT04205630 | SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma | completed | Phase 2 | 64 | Byondis B.V.INDUSTRY | 7 | May 30, 2024 | clinicaltrials |
| NCT03926936 | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study(FUCHSia) | completed | Phase 2 | 17 | Frederic AmantOTHER | 2 | May 28, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT02164461 | Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer | completed | Phase 1 | 12 | Advaxis, Inc.INDUSTRY | 1 | May 20, 2024 | clinicaltrials |
| NCT06417736 | Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women | recruiting | N/A | 75 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06413992 | Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | recruiting | Phase 2 | 117 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT04823065 | 4FMFES-PET Imaging of Endometrial and Ovarian Cancers | completed | Phase 1 / Phase 2 | 53 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT04972682 | [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer(SENTRY) | completed | N/A | 102 | Moscow City Oncology Hospital No. 62OTHER_GOV | 1 | May 7, 2024 | clinicaltrials |
| NCT01649089 | Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer | unknown | N/A | 224 | GOG FoundationNETWORK | 3 | May 3, 2024 | clinicaltrials |
| NCT05107739 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | terminated | Phase 1 | 5 | Nurix Therapeutics, Inc.INDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT06394258 | POSE - POs Surgery Endometrial Cancer(POSE) | completed | N/A | 30 | Fundacao ChampalimaudOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06046274 | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer | withdrawn | Phase 2 | 0 | GenmabINDUSTRY | 6 | Apr 30, 2024 | clinicaltrials |
| NCT05378152 | Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity | completed | N/A | 82 | Royal College of Surgeons, IrelandOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT05931445 | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | active not recruiting | N/A | 500 | Comprehensive Support Project for Oncology ResearchOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT05877404 | Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer | terminated | — | 112 | Wake Forest University Health SciencesOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT01526655 | Robot Assisted Laparoscopic Hysterectomy vs. Abdominal Hysterectomy in Endometrial Cancer | completed | N/A | 50 | University Hospital, LinkoepingOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT06354738 | Improving Endometrial Cancer Assessment by Combining Genomic Profiling and Surgical Assessment(EUGENIE) | recruiting | N/A | 1,000 | University Hospital, GasthuisbergOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT04298827 | Gyn Onc Prehab Study | completed | N/A | 83 | St. Louis UniversityOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT05390021 | PET/MRI in Endometrial Cancer | withdrawn | N/A | 0 | Massachusetts General HospitalOTHER | 0 | Apr 2, 2024 | clinicaltrials |
| NCT06341855 | Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer | unknown | N/A | 100 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04743999 | Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma | terminated | Phase 2 | 9 | Henry Ford Health SystemOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT06049693 | Iron Prehabilitation in Endometrial Cancer(IROGYN) | completed | Phase 4 | 156 | National and Kapodistrian University of AthensOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Haihe Biopharma Co., Ltd.INDUSTRY | 3 | Mar 21, 2024 | clinicaltrials |
| NCT01886066 | Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer(EndoSLN) | completed | N/A | 156 | University Health Network, TorontoOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
| NCT03189446 | Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer | completed | Phase 2 | 39 | University of OklahomaOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06294886 | Vaginal Fluid Collection for Detection of Endometrial Cancer | unknown | — | 40 | Innovis LLCINDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06206083 | Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis | recruiting | — | 64 | National Institute of CancerologíaOTHER_GOV | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06279832 | Radiomics and Radiogenomics Models to Predict Molecular Integrated Risk Classes and Prognostic Factors in Endometrial Cancer.(Romantic) | unknown | N/A | 1,000 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05728814 | DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer(DORA) | unknown | — | 100 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06273878 | From Fetal-maternal Interface Immune Tolerance to Endometrial Cancer Immune Escape: Potential Targets for Immunotherapy | unknown | — | 80 | Regina Elena Cancer InstituteOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05737797 | Non-Invasive Diagnosis of Endometrial Cancer(NIECE) | unknown | N/A | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT03476798 | Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium(Clovis-001) | completed | Phase 2 | 49 | University of OklahomaOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT02730923 | Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)(VICTORIA) | unknown | Phase 1 / Phase 2 | 72 | Centre Leon BerardOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04149691 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | unknown | Phase 1 | 42 | Celon Pharma SAINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03015129 | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | completed | Phase 2 | 80 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06238284 | HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China | unknown | — | 300 | Chongqing University Cancer HospitalOTHER | 0 | Feb 2, 2024 | clinicaltrials |
| NCT05529303 | Prolonged Grief and Perception of Femininity in Gynecological Cancer Patients | completed | N/A | 80 | Kevser PamukOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05738902 | Adherence and Compliance to ERAS in Gynecological Surgery(ERASGYNBS002) | unknown | — | 600 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06066216 | Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer | not yet recruiting | Phase 2 | 45 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 23, 2024 | clinicaltrials |
| NCT00342446 | A Follow-up Study of Women Evaluated and Treated for Infertility | completed | — | 12,193 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Jun 12, 2024source: clinicaltrials